6月12日，Praxis Precision Medicines盘中上涨5.02%，报250.24美元/股，成交额4819.03万美元。
消息面上，此前公司核心药物Vormatrigine癫痫临床试验主要终点虽未达标，但试验达到50%应答率的关键次要终点，30毫克剂量组癫痫发作减少更为显著，且因不良事件停药率低于10%、耐受性良好。经过前期持续回调消化利空后，市场开始重新评估次要终点数据价值及药物安全性优势，推动股价出现阶段性修复反弹。不过，主要终点未达标对后续开发路径构成的不确定性仍需关注。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.